AbbVie's biggest deal since 2019 could land soon

1 hour ago 7

AbbVie (ABBV) is closing successful connected a woody to bargain Apogee Therapeutics for $10.9 cardinal successful cash, according to a Reuters study citing radical acquainted with the substance successful the Financial Times.

The terms values Apogee astatine a astir 60% premium to its closing stock terms connected Thursday, June 18, a steep markup for a institution that has ne'er sold a azygous approved drug.

AbbVie usually reaches for biotechs with marketed products oregon precocious signifier information successful hand, not 1 inactive years from its archetypal launch.

An announcement could travel arsenic aboriginal arsenic Monday, June 22, Reuters noted, provided negotiations wrapper up without last-minute issues. Neither institution has confirmed the talks publicly, and AbbVie and Apogee did not instantly respond to requests for comment, partially due to the fact that AbbVie's U.S. offices were closed for Juneteenth.

The spread betwixt Apogee's stand-alone worth and the connection terms tells its ain story. Apogee's shares were up astir 20% truthful acold this year, giving it a marketplace capitalization of astir $6.8 billion, according to Reuters.

A $10.9 cardinal cheque is astir 60% much than that, which means AbbVie is paying not conscionable for what Apogee has built, but besides for what it mightiness beryllium retired later.

Apogee's pipeline rests connected a azygous cause campaigner

Apogee Therapeutics (APGE) is simply a objective signifier biotech with nary commercialized products, gathering antibody drugs for inflammatory and immune diseases specified arsenic atopic dermatitis, asthma, and chronic obstructive pulmonary disease, the company's pipeline leafage says.

Its pb candidate, zumilokibart, blocks a cytokine called IL-13 that drives tegument inflammation successful atopic dermatitis.

Related: OpenAI admits enterprises request amended power implicit AI costs

That matters for patients due to the fact that Apogee's ain proceedings information amusement the cause tin support results with dosing arsenic infrequent arsenic doubly a year, the institution reported, compared with up to 26 injections annually for immoderate existing treatments.

That committedness already drew extracurricular superior earlier AbbVie showed up. In May, Apogee secured up to $1.3 cardinal successful financing from Blackstone Life Sciences to money a Phase 3 proceedings and a imaginable motorboat without selling much stock. AbbVie would beryllium buying into that aforesaid bet, conscionable years earlier immoderate regulatory verdict.